Selection of high-transition temperature Phospholipids (HSPC, DPPC, or DOPE) to create rigid, oxygen-barrier bilayers
For patients with uncertain family history or unexplained hepatic or neurological symptoms that could be consistent with Wilsons disease, evaluation should precede GHK-Cu therapy
PMID: 12197785

Reconstitution Reference 5 mg, 10 mg, and 20 mg Injection Vials Vial Size 5 mg BAC Water 1.0 mL Concentration 5,000 mcg/mL 250 mcg 5 units (0.05 mL) 500 mcg 10 units (0.10 mL) 1 mg 20 units (0.20 mL) 5 mg 100 units (1.00 mL) Vial Size 5 mg BAC Water 2.0 mL Concentration 2,500 mcg/mL 250 mcg 10 units (0.10 mL) 500 mcg 20 units (0.20 mL) 1 mg 40 units (0.40 mL) 5 mg Full vial Vial Size 5 mg BAC Water 3.0 mL Concentration 1,667 mcg/mL 250 mcg 15 units (0.15 mL) 500 mcg 30 units (0.30 mL) 1 mg 60 units (0.60 mL) 5 mg Vial Size 10 mg BAC Water 2.0 mL Concentration 5,000 mcg/mL 250 mcg 5 units (0.05 mL) 500 mcg 10 units (0.10 mL) 1 mg 20 units (0.20 mL) 5 mg 100 units (1.00 mL) Vial Size 10 mg BAC Water 5.0 mL Concentration 2,000 mcg/mL 250 mcg 12.5 units (0.125 mL) 500 mcg 25 units (0.25 mL) 1 mg 50 units (0.50 mL) 5 mg Vial Size 20 mg BAC Water 5.0 mL Concentration 4,000 mcg/mL 250 mcg 6 units (0.06 mL) 500 mcg 12.5 units (0.125 mL) 1 mg 25 units (0.25 mL) 5 mg 125 units (1.25 mL) Concentrations rounded for the table

Under cold-growth conditions, Ballester-Toms et al